BSACI 2026: New preference and ease-of-use data comparing EURneffy® nasal adrenaline spray and adrenaline auto-injector trainer devices
New scientific data suggest that fear, stress and the physical bulk of AAIs are significant, often underappreciated barriers that may prevent many people at risk of anaphylaxis from consistently carrying or using their emergency anaphylaxis treatment.1-3 Findings from studies conducted by ALK were presented at the 2026 British Society for Allergy and Clinical Immunology (BSACI) Conference in Newport, Wales.
Covered in this story
Call it yourself
No calls on $ALK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alaska Air Group →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.